Toogood PL - Search Results

1

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Fry DW, et al. Among authors: toogood pl. Mol Cancer Ther. 2004 Nov;3(11):1427-38. Mol Cancer Ther. 2004. PMID: 15542782

2

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL. VanderWel SN, et al. Among authors: toogood pl. J Med Chem. 2005 Apr 7;48(7):2371-87. doi: 10.1021/jm049355+. J Med Chem. 2005. PMID: 15801830

3

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW. Toogood PL, et al. J Med Chem. 2005 Apr 7;48(7):2388-406. doi: 10.1021/jm049354h. J Med Chem. 2005. PMID: 15801831

4

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

Bathini Y, Singh I, Harvey PJ, Keller PR, Singh R, Micetich RG, Fry DW, Dobrusin EM, Toogood PL. Bathini Y, et al. Among authors: toogood pl. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3881-5. doi: 10.1016/j.bmcl.2005.05.131. Bioorg Med Chem Lett. 2005. PMID: 15993068

5

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E. Barvian M, et al. J Med Chem. 2000 Nov 30;43(24):4606-16. doi: 10.1021/jm000271k. J Med Chem. 2000. PMID: 11101352

6

Cyclin-dependent kinase inhibitors for treating cancer.

Toogood PL. Toogood PL. Med Res Rev. 2001 Nov;21(6):487-98. doi: 10.1002/med.1021. Med Res Rev. 2001. PMID: 11607930 Review.

7

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. Baughn LB, et al. Among authors: toogood pl. Cancer Res. 2006 Aug 1;66(15):7661-7. doi: 10.1158/0008-5472.CAN-06-1098. Cancer Res. 2006. PMID: 16885367

8

The kinome is not enough.

Toogood PL. Toogood PL. Chem Biol. 2005 Oct;12(10):1057-8. doi: 10.1016/j.chembiol.2005.09.011. Chem Biol. 2005. PMID: 16242646 Review.

9

Progress toward the development of agents to modulate the cell cycle.

Toogood PL. Toogood PL. Curr Opin Chem Biol. 2002 Aug;6(4):472-8. doi: 10.1016/s1367-5931(02)00342-3. Curr Opin Chem Biol. 2002. PMID: 12133723 Review.

10

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S. Menu E, et al. Among authors: toogood pl. Cancer Res. 2008 Jul 15;68(14):5519-23. doi: 10.1158/0008-5472.CAN-07-6404. Cancer Res. 2008. PMID: 18632601

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page